Thursday, December 25, 2025
ADVT 
National

No unexpected effects from COVID-19 shots so far

Darpan News Desk The Canadian Press, 08 Jan, 2021 06:26 PM
  • No unexpected effects from COVID-19 shots so far

Health Canada has no reports of unexpected side-effects from patients vaccinated against COVID-19 thus far.

"There haven't been any serious adverse events, or even the mild and moderate adverse events, that have been out of line or different than what we've seen in the clinical trials," Dr. Supriya Sharma said in an interview with The Canadian Press Friday.

Sharma, Health Canada's chief medical adviser, is overseeing the vaccine review process.

She said experts look for two things when reviewing data after vaccines are given. The first is whether anything happens that was not observed during the clinical trials, and the second is whether the side-effects that were documented during the trials are more severe or greater in number than what the trials saw.

The answer to both questions in Canada so far is no, said Sharma.

"It seems that the clinical trials are pretty representative," she said.

The most common side-effects from the vaccines are short-term fever, pain at the injection site, headache and fatigue. Most subside within 24 hours.

Health Canada approved two vaccines for COVID-19 in December, including one from Pfizer and BioNTech and a second from Moderna.

Vaccinations began Dec. 14, and data aggregated by University of Saskatchewan student Noah Little shows about 230,000 doses have been given so far. Most of the first doses went to front-line hospital staff and long-term care workers and a smaller number of long-term care residents.

Vaccines began reaching some First Nations and northern territories this week.

Health Canada continues to review data from two other vaccine developers, AstraZeneca and Johnson & Johnson, but is still awaiting more data from the companies. Sharma said she can't say when Health Canada would be ready to make a decision about either one.

Both companies are expected to complete Phase 3 clinical trials in the United States this month.

MORE National ARTICLES

Review board limits freedoms for man who killed five

Review board limits freedoms for man who killed five
Matthew de Grood, who is now 29, was found not criminally responsible for the 2014 killings of Zackariah Rathwell, Jordan Segura, Kaitlin Perras, Josh Hunter and Lawrence Hong, because he was suffering from schizophrenia at the time.

Review board limits freedoms for man who killed five

Man sentenced to life for Indigenous woman's death

Man sentenced to life for Indigenous woman's death
Michael William Okemow, 40, was found guilty of second-degree murder in the 2015 beating death of Crystal Andrews, 22, at God's Lake First Nation, a Swampy Cree and Metis community located about 1,000 kilometres northeast of Winnipeg.

Man sentenced to life for Indigenous woman's death

Ethics watchdog bites ex-ambassador to U.S.

Ethics watchdog bites ex-ambassador to U.S.
David MacNaughton was Prime Minister Justin Trudeau’s point man in Washington for 3 1/2 years before he left one year ago.

Ethics watchdog bites ex-ambassador to U.S.

Damaged cars being removed from derail site: CN

Damaged cars being removed from derail site: CN
The CP freight train was hauling potash, a non-hazardous, potassium-rich type of salt, when the cars left the bridge, dumping some of the material into a nearby creek.

Damaged cars being removed from derail site: CN

WATCH: Canada-US Border Closure Extended Till November | BC State of Emergency To Stay

WATCH: Canada-US Border Closure Extended Till November | BC State of Emergency To Stay
The US Canada border closure remains in place and at the eleventh hour US backs down on aluminum tariff dispute with Canada.

WATCH: Canada-US Border Closure Extended Till November | BC State of Emergency To Stay

Study hints antibody drug may cut COVID-19 hospitalizations

Study hints antibody drug may cut COVID-19 hospitalizations
The company said it would talk with regulators about possible next steps but that it was too soon to speculate on whether these interim results might lead to any action to allow early use.

Study hints antibody drug may cut COVID-19 hospitalizations